Adam Feuerstein

An Otsuka drug succeeded in a Phase 3 study in a chronic kidney disease, with results that outperformed a competitor's recent data.

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help, STAT's Adam Feuerstein writes.

And on the fourth day of ASCO, Big Pharma gave to me...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer, a new study found.

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study presented at an ASCO meeting.

Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head study, produced mixed results in a new trial.

A Merus drug, combined with Keytruda, shows preliminary survival gains in newly diagnosed metastatic head and neck cancer

'Oh no, another Adam rant': True, but STAT's Adam Feuerstein says it's totally justified. It's reality check time in biotech.

Tourmaline Bio said its experimental antibody treatment demonstrated deep reductions in a measure of inflammation often tied to heart disease

Tourmaline Bio said its experimental antibody treatment demonstrated deep reductions in a measure of inflammation often tied to heart disease

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service? Find out on "The Readout LOUD" podcast.

Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or the other.

Cytokinetics committed an unforced error that has extended the review of its heart disease drug, knocked down its stock price, and triggered the ire of investors.

The biotech mood check lately? Happy, says STAT's Adam Feuerstein.

While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”

The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood cancer.

STAT's Adam Feuerstein puts all his “Biotech Doom Loop” panic-mongering aside, as he embraces luminescent moonbeams and downy-soft puppies: "Biotech is back, baby!"

Biotech entrepreneur Sam Waksal has been accused of "reckless conduct," including using a veterinary medicine on a severely ill child that was unapproved for human use, in a new lawsuit.

The biotech company Immunovant announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner greater control over its operations.